Get email alerts on the Health Care topic
No spam. Unsubscribe anytime.
Senate passes technical changes to Prescription Drug Affordability Board reporting
Summary
Senators approved Senate Bill 289 A to change reporting and workload provisions for the Prescription Drug Affordability Board, moving one required report from quarterly to annual and allowing reviews of up to nine drugs per year.
Senators on March 24 passed Senate Bill 289 A, enacting technical changes to statutes governing the Prescription Drug Affordability Board (PDAB).
Senator Patterson, the carrier, said the bill converts a quarterly Department of Consumer and Business Services list of drugs exceeding price thresholds into a yearly report. It also changes PDAB’s mandate from reviewing nine drugs per year to up to nine drugs per year and allows PDAB to include generic market status in an annual report to the health care cost growth target program instead of issuing a separate report.
Patterson described the changes as “housekeeping” recommended by PDAB in its 2024 annual report to the Legislature. The measure was advanced on third reading and declared passed after a roll call; the Clerk announced that the bill had received a constitutional majority.
The law will shorten the frequency of one administrative report, give the board flexibility in the number of affordability reviews it undertakes annually, and consolidate reporting about generic drug market status into the annual PDAB reporting stream.
AI generated
The text on this page is AI generated. Summaries, highlights, analysis, and video transcripts are all produced from the original source material.
AI can make mistakes, so if you spot one, and we will fix it for everyone.
Note: the source content is unaltered by us. Any content source we link to, be it a video, an audio recording, or a document, is presented exactly as its publisher released it. That publisher is usually a government body, sometimes an individual official or another organisation.
